Merck KGaA Stock

GLP-1 drugs are more popular than ever. This week, polling organization Gallup reported that 11% of U.S. adults are currently taking GLP-1 medications for weight loss, which is a huge jump from the

Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified

Bio-Techne (NASDAQ:TECH), a life science reagents, instruments, and bioprocessing tools provider, closed at $70.67, up 20.02%. Merck KGaA’s $73-per-share cash offer drove the move, and investors are

Pfizer (NYSE:PFE), a large-cap biopharmaceutical company focused on medicines, vaccines, and specialty therapeutics, closed at $25.21, down 2.74%. This morning's CFO transition announcement and

Explore the exciting world of Merck (NYSE: MRK) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends

Organon (NYSE:OGN), a women’s health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon

The pharmaceutical industry is a good place to look for solid dividend stocks. Since they offer lifesaving therapies, drugmakers generally see consistent demand for their products, even amid severe

Terns Pharmaceuticals (NASDAQ: TERN) had a more memorable March than a great many other companies on U.S. stock exchanges. That's largely because it agreed to be bought out by a much larger peer

Over the past year, Merck's (NYSE: MRK) shares have climbed by 46%. That seems a bit surprising. Last year, the company's financial results were relatively weak as it faced declining revenue for one

If you're at all interested in the pharmaceutical sector, you may be overwhelmed by the opportunity for GLP-1 weight-loss therapies. Sure, that's an important new drug category, but it isn't the

Pharmaceutical giant Eli Lilly (NYSE: LLY) has been the winner in the massive GLP-1 drug category, the class of medications that have proven extremely effective in lowering blood sugar levels and

Guardant Health (NASDAQ: GH) is on the rise, in more ways than one.

Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several

The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and Merck (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There

Some investors believe the market is currently overvalued. Hype and optimistic expectations, especially for artificial intelligence (AI) stocks, are baked into equity prices, or so the argument